Sign Out
Liver tests: Patients given ursodeoxycholic acid should have SGPT (ALT), SGOT(AST), GGT, ALP and bilirubin measured at the initiation of therapy and thereafter as indicated by the particular clinical circumstances. Monitoring of serum values is recommended upon initiation of treatment, every 1 to 3 months for the first 3 months of treatment (depending on the indication for use), and then every 6 months during treatment; ursodeoxycholic acid must be discontinued if increased values persist.
Use in Pregnancy & Lactation: Should not be used during pregnancy and lactation without medical advice.
Use in Children: Safety and efficacy have not been established.
